Cooperative Agreement U1A28550

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $306,870 to Kinetiq Therapeutics LLC, a life science startup in Texas, to conduct proof-of-concept studies on an enzyme replacement therapy (ERT) for Fanconi anemia. Fanconi anemia is a rare inherited disease characterized by bone marrow failure and malignancies. The project aims to demonstrate the feasibility of using an...

This Project Grant award of $390,000.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research on a novel mutation in the TASPASE1 gene and its impact on hematopoiesis and transcriptional regulation. The principal investigator at the University of Colorado-Denver is investigating how the TASPASE1V343M mutation disrupts proteolytic cleavage of the transcription factor TFIIA, leading...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will provide $646,383 to Emory University to evaluate the impact of donor and recipient factors on the survival of transfused red blood cells (RBCs) in recipients with sickle cell disease. The research aims to examine mechanisms contributing to RBC clearance in both the recipient and the donor, including the impact of RBC...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $300,000 to Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease. The project aims to test a novel lentiviral vector technology for efficiently editing hematopoietic stem cells to knockout the BCL11A enhancer, a key genetic target for sickle cell treatment. Through in vitro assays, the Phase I effort will...

This Project Grant award, valued at $801,000.00, was provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The funding supports research at The Children's Hospital Corporation, doing business as Boston Children's Hospital, to investigate the role of stress granules in red blood cell development, particularly during stress conditions. The research aims to uncover the...

This federal Project Grant award of $225,101 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research to investigate the mechanisms underlying the increased risk of hematological malignancies in sickle cell disease patients. The key objectives of this 2-year project are to: 1) Perform experiments to understand how increased oxidative stress and DNA damage in hematopoietic stem and progenitor cells lead to the development of clonal...

This $445,000 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at The Children's Hospital of Philadelphia (CHOP) to investigate how the tropomyosin 1 gene product impacts the development of hematopoietic stem and progenitor cells and their precursors. The goal is to define genetic determinants of hematopoiesis that could enhance in vitro production of blood cells to support research and development of blood...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,017,232 Project Grant to New Health Sciences, Inc. (doing business as Hemanext Inc.) to rigorously assess the efficacy of hypoxic red blood cell (HRBC) transfusions compared to conventional red blood cell (CRBC) transfusions in patients with sickle cell anemia. This 3-year project aims to evaluate the potential of HRBC transfusions as an alternative treatment...

This $662,949 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is supporting the development of innovative cell and gene therapy strategies to treat Fanconi anemia (FA), a leading cause of inherited bone marrow failure. The award to The Leland Stanford Junior University aims to establish stable hematopoiesis in FA patients without the use of genotoxic chemotherapy or irradiation. Key objectives include generating targeted...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $213,284 award to the Rector & Visitors of the University of Virginia (UVA) supports research to decipher the molecular mechanisms by which systemic iron homeostasis regulates endothelial function and hemoglobin alpha (HBA) expression in the microvasculature. The central hypothesis...